Elan & Athena: Selling out, Trading up
Executive Summary
Athena's frustration with Wall Street and with its Big Pharma partners clearly led to its willingness to listen to Elan's acquisition offer-other similarly placed biotechs are likely to abandon strategies focused on independence.